Excivion announces results of an international collaboration evaluating the utility of its novel point-of-care dengue and Zika antibody tests
CAMBRIDGE UK – Excivion Ltd (www.excivion.com), a biotechnology company developing novel vaccines based on its proprietary glycan-cloaking molecular design and adjuvant platforms, today announces the publication of a peer-reviewed article in Frontiers in Immunology (Echegaray et al. July 23, 2021, doi: 10.3389/fimmu.2021.703887) which demonstrates the unique performance advantages and versatility
27/10/2023